OICHARTS
8 AMThe 8 AM report →

INCY

Incyte Genomics Inc · XNAS · 131 sessions on record
$121.35▼ −1.85 · −1.5%from $123.20 the session before · Sep 30, 2026 close · end of day
Open
$123.00
High
$124.23
Low
$121.03
Day's range
$3.22.6% of the previous close
VWAP
$121.98close −0.52% from it
Volume, shares
1.62M1.06× the 20-session average
Traded, $
$197.6M
Trades
25.8K63 shares per trade
Previous close
$123.20−1.85 to the close
Market cap
$24.24Bat the close of Sep 30
Day range10% of the way up
$121.03$124.23
52-week range74% of the way up
$90.08 Mar 30$132.60 Jul 28

−8.5% from the high · +35% from the low

Options

No listed options on INCY

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
INCY close over the last 126 sessions, with S&P 500 rebased to the first close92.24113.13134.02axis spans 45%S&P 500INCYApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 45 percent.

Quarterly results

consolidated · latest filed Apr 28, 2026 · SEC filings

Revenue $1.27B, +21% on a year earlier; profit $303.3M, +92% in the Mar 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of INCY on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Mar 2026filed Apr 28$1.27B▲ +21%$303.3M▲ +92%1.47▲ +1.4%S&P 500 0.0% · +1.4 pp
Dec 2025filed Feb 10$1.51B▲ +28%$299.3M▲ +49%1.46—not reached
Sep 2025filed Oct 28$1.37B▲ +20%$424.2M▲ +300%2.11—not reached
Jun 2025filed Oct 28$1.22B▲ +16%$405.0M—2.04—not reached
Mar 2025filed Apr 28$1.05B▲ +20%$158.2M▼ −6.7%0.80▲ +1.4%S&P 500 0.0% · +1.4 pp
Dec 2024filed Feb 10$1.18B▲ +16%$201.2M▲ +0.07%0.90—not reached
Sep 2024filed Oct 28$1.14B▲ +24%$106.5M▼ −38%0.54—not reached
Jun 2024filed Oct 28$1.04B▲ +9.3%−$444.6M▼ −320%-2.04—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of INCY on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025$5.14B▲ +21%$1.29B▲ +3,800%6.41
FY24to Dec 2024$4.24B▲ +15%$32.6M▼ −95%0.15
FY23to Dec 2023$3.70B▲ +8.9%$597.6M▲ +75%2.65
FY22to Dec 2022$3.39B▲ +14%$340.7M▼ −64%1.52
FY21to Dec 2021$2.99B▲ +12%$948.6M—4.27

Fundamentals

consolidated · filings to Mar 2026 · close $121.35 on Sep 30

INCY trades at 17 times trailing earnings, 4.3 times book value, revenue +21% over twelve months, market cap $24.24B.

Valuation
Market cap
$24.24Bon Sep 30
Price to earnings
17consolidated · four quarters to Mar 2026
Trailing EPS
$7.08diluted · consolidated · four quarters to Mar 2026
Price to book
4.3consolidated · balance sheet to Mar 2026
Book value a share
$28.14consolidated · balance sheet to Mar 2026
Debt to equity
—
Return on equity
31%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
4.5market cap over revenue, four quarters to Mar 2026
Shares outstanding
200Mon Sep 30
Growthsums of the four quarters filed to Mar 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
$5.36Bfour quarters to Mar 2026
Revenue growth, 12 months
▲ +21%against the twelve months before
Revenue 3-year CAGR
▲ +16%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
$1.43Bfour quarters to Mar 2026
Profit growth, 12 months
▲ +6,600%against the twelve months before
Profit 3-year CAGR
▲ +64%trailing twelve months against the twelve months 3 years earlier · consolidated

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 190% of shares, BAKER BROS. ADVISORS LP the largest at 31%, BlackRock, Inc. 18% and Dodge & Cox 12%, as filed for the quarter to Jun 2026.

Held by 13F managers
190%of shares outstanding
Shares held
389M−1.2% on Mar 2026 among managers filing both
Managers holding
806764 a quarter earlier
Largest holder
31%BAKER BROS. ADVISORS LP
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of INCY
ManagerSharesOf outstandingValueChange on quarter
BAKER BROS. ADVISORS LP61.5M31%$6.97B+35.8K
BlackRock, Inc.36.1M18%$4.09B−1.89M
Dodge & Cox23.9M12%$2.71B−590K
VANGUARD CAPITAL MANAGEMENT LLC22M11%$2.50B+188K
STATE STREET CORP19.4M9.7%$2.20B+162K
VANGUARD PORTFOLIO MANAGEMENT LLC15.6M7.8%$1.77B+63.8K
AQR CAPITAL MANAGEMENT LLC10.6M5.3%$1.21B−974K
GEODE CAPITAL MANAGEMENT, LLC9.5M4.8%$1.07B+95.1K
Invesco Ltd.8.16M4.1%$925.1M+419K
WELLINGTON MANAGEMENT GROUP LLP7.15M3.6%$810.6M+619K
Insider tradesSEC Forms 3, 4 and 5 · the latest 10

No open-market insider buying or selling in the last 90 days.

INCY insider trades
InsiderTradeSharesPriceHeld after
HARRIGAN EDMUNDDirectorgranted · Jun 8, 20261,642$0.0022,764
BAKER BROS. ADVISORS LPDirector,TenPercentOwnergranted · Jun 8, 20261,642$0.0028,205,360
BAKER BROS. ADVISORS LPDirector,TenPercentOwnergranted · Jun 8, 20261,642$0.002,834,681
BRAWLEY OTIS WDirectorgranted · Jun 8, 20261,642$0.0012,894
BIENAIME JEAN JACQUESDirectorgranted · Jun 8, 20261,642$0.0024,424
FOUSE JACQUALYN ADirectorgranted · Jun 8, 20261,642$0.0020,968
Clancy Paul JDirectorgranted · Jun 8, 20261,642$0.0025,383
High Katherine ADirectorgranted · Jun 8, 20261,642$0.0014,983
Tray ThomasOfficersold · Jun 4, 20262,639$100.0021,132
Tray ThomasOfficerexercised · Jun 4, 20262,639$83.8323,771

Corporate actions

exchange records

No corporate action on record for INCY yet.

Price history

131 sessions on record · to Sep 30 · end of day

INCY is −2.9% over 20 sessions against the S&P 500's +0.1%, 8.5% below its 52-week high, realised volatility 25% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $INCY %S&P 500 %Difference pp
120 sessionssince Apr 9$96.96▲ +25%▲ +12%+13
60 sessionssince Jul 7$118.04▲ +2.8%▲ +2.0%+0.80
20 sessionssince Sep 1$125.01▼ −2.9%▲ +0.11%−3.0
5 sessionssince Sep 23$124.64▼ −2.6%▼ −0.67%−2.0
1 sessionsince Sep 29$123.20▼ −1.5%▼ −0.21%−1.3
Averages of the closeclose against each average
5-session average
$123.54close −1.8% from it
20-session average
$124.71close −2.7% from it
50-session average
$123.63close −1.8% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$3.22.6% of the close
Average day's range, 20
$3.22.6% of the close
Volume against 20 sessions
1.06×1.62M vs 1.56M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
25%≈ ±1.6% a session · moved more than that on 8 of 20
Realised volatility, 60
31%≈ ±1.9% a session · moved more than that on 12 of 60
Beta to S&P 500, 60
0.25moved with S&P 500 on 36 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
7 up · 13 downof 20
Last 60 sessions
26 up · 34 downof 60
Best session, 250
▲ +9.3%Jul 28
Worst session, 250
▼ −6.0%Jun 15

Incyte Genomics Inc is held by

1 headlines on INCY

latest Sep 30, 2026 · links go to the publisher

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 67% of reported volume on Sep 30, 2026, against 64% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
INCY daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 2026336K502K66.9%
Sep 29, 2026434K599K72.5%
Sep 28, 2026342K557K61.3%
Sep 25, 2026322K458K70.4%
Sep 24, 2026276K434K63.6%
Sep 23, 2026245K459K53.3%
Sep 22, 2026293K462K63.3%
Sep 21, 2026275K419K65.6%
Sep 18, 2026419K527K79.6%
Sep 17, 2026261K388K67.3%

Filings

SEC EDGAR · newest first
INCY SEC filings
FiledFormReport date
Sep 24, 20264Sep 22, 2026
Sep 17, 20264Sep 15, 2026
Sep 15, 2026144—
Aug 31, 20268-KAug 31, 2026
Aug 27, 20264Aug 25, 2026
Aug 20, 20264Aug 19, 2026
Aug 19, 2026144—
Aug 14, 20264Aug 12, 2026
Aug 12, 2026144—
Aug 7, 20264Aug 5, 2026
Aug 7, 20264Aug 5, 2026
Aug 5, 2026144—
Aug 5, 2026144—
Aug 4, 20264Jul 31, 2026
Aug 4, 20264Jul 31, 2026
Aug 3, 2026144—
Jul 31, 2026144—
Jul 31, 2026144—
Jul 28, 202610-QJun 30, 2026
Jul 28, 20268-KJul 28, 2026
Jul 27, 20264Jul 23, 2026
Jul 27, 20264Jul 23, 2026
Jul 20, 20264Jul 16, 2026
Jul 20, 20264Jul 16, 2026
Jul 20, 20264Jul 16, 2026

About Incyte Genomics Inc

SEC and exchange records
Company
Incyte Genomics Inc
Exchange
XNAS
SEC CIK
879169
Sessions on record
131
Price source
End of day · delayed
Computed
2 Oct, 01:46 am IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.